AUD $5.3m R&D Rebate Received
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The rebate reflects R&D activities conducted both locally and internationally, providing the company with non-dilutive funding for its ongoing clinical trials and development programs. The CEO emphasized that this funding will bolster their R&D efforts, particularly in combating antibiotic-resistant infections.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- RCE Awarded Advanced Overseas Finding up to A$85m
- Hong Kong Patent Granted for RECCE Anti-Infectives
- Positive Efficacy Data for Inhaled R327 in HAP/VAP Model
- Patient Dosing Underway in Ph 3 Indonesia DFI Trial
- Preliminary Final Report
Later from Recce Pharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Recce Enters Second U.S. Department of Defense R&D Agreement
- Appendix 4D and Interim Financial Report
- RCE Investor Webinar Presentation Deck
- Brazil Patent Granted for RECCE Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals